Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

UCB Stem Cells for Autism Spectrum Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04710810
Recruitment Status : Active, not recruiting
First Posted : January 15, 2021
Last Update Posted : January 15, 2021
Sponsor:
Information provided by (Responsible Party):
St. Petersburg Bekhterev Research Psychoneurological Institute

Brief Summary:

Purpose. The goals of the study are to assess the safety of the intravenous infusion of umbilical cord blood (UCB) cells in patients with autism and to confirm changes in social/ communicative skills and cognitive functioning after four infusions of ABO/Rh-matched UCB stem cells.

Material and methods. The sample comprises 30 patients (27 males, 3 females) aged between 3 and 11 years with ASD under the care of the National Medical Research Center for Psychiatry and Neurology (Saint-Petersburg, Russia). Participants are randomly assigned to either the control group (14 males, 1 female) or the experimental group (13 males, 2 females). The experimental group receives intravenous injections of UCB cells four times with a two-week gap between injections. The control group receives standard therapy.

The dynamic of cognitive functions and social/communicative skills assess with Checklist for autism spectrum disorders (CASD), Autism treatment evaluation checklist (ATEC), subscales of Wechsler Intelligence Scale for Children (WISC) - "Digit Span", "Picture completion", "Block design", "Coding".


Condition or disease Intervention/treatment Phase
Autism Spectrum Disorder Other: umbilical cord blood mononuclear stem cells Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transplantation of Human Allogenic Cord Blood Mononuclear Stem Cells in Autism: Safety and Efficacy of the Method
Actual Study Start Date : November 4, 2019
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : February 28, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental
Patients receive group and rhesus compatible UCB cells through intravenous bolus injections (4 injections at 2-week intervals) after pre-medication with Clemastine (0.025 mg/kg body weight, intravenously). One dose is 250±10 x 10⁶ viable cells per sample.
Other: umbilical cord blood mononuclear stem cells
UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.

No Intervention: Control
Patients receives standard therapy (applied behavioral analysis, speech therapy).



Primary Outcome Measures :
  1. Incidence of Treatment Emergent Adverse Events [ Time Frame: 24 hours after infusion ]

    Assessed by Adverse Event Grading Scale. It categorized adverse events according to severity.

    Mild Adverse Event - event results in mild or transient discomfort, not requiring intervention or treatment; does not limit or interfere with daily activities (e.g., insomnia, mild headache).

    Moderate Adverse Event - event is sufficiently discomforting so as to limit or interfere with daily activities; may require interventional treatment (e.g., fever requiring antipyretic medication).

    Severe and undesirable Adverse Event - event results in significant symptoms that prevent normal daily activities; may require hospitalization or invasive intervention (e.g., anemia resulting in blood transfusion).


  2. Changes in severity of autistic symptoms from baseline at 3d and 6th month (measured by Checklist for Autism Spectrum Disorders (CASD) [ Time Frame: at baseline, 3d and 6th month ]
    The CASD rates 30 symptoms of autism, covering six domains: problems with social interaction, perseveration, somatosensory disturbance, atypical communication and development, mood, problems with attention and safety. Symptoms are scored as present or absent based on information drawn from various sources, including teacher, caregiver, parent, observation of the child, and available records. The scores from each subscale are combined in order to calculate a Total Score, which ranges from 0 to 30 points. A lower score indicates less severe symptoms of ASD and a higher score correlates with more severe symptoms of ASD.

  3. Changes in severity of autistic symptoms from baseline at 3d and 6th month (measured by Autism Treatment Evaluation Checklist (ATEC) [ Time Frame: at baseline, 3d and 6th month ]
    The purpose of the ATEC is to measure a change in a patient due to various interventions. It consists of four subtests: Speech/Language Communication (14 items); Sociability (20 items); Sensory/ Cognitive Awareness (18 items); Health/Physical/Behavior (25 items). The scores from each subscale are combined in order to calculate a Total Score, which ranges from 0 to 179 points. A lower score indicates less severe symptoms of ASD and a higher score correlates with more severe symptoms of ASD.


Secondary Outcome Measures :
  1. "Digit Span" subscale of Wechsler Intelligence Scale for Children (WISC) [ Time Frame: at baseline, 6th month ]
    It assesses short-term auditory memory, concentration. The child is asked to repeat dictated series of digits forwards and other series backwards. Series begin with two digits and keep increasing in length, with two trials at each length. A primary score ranges from 0 to 9 points for forward series and from 0 to 8 points for backward series. The primary score is further converted into a final score in accordance with the age of the patient. A higher score correlates with better cognitive functioning.

  2. "Picture completion" subscale of Wechsler Intelligence Scale for Children (WISC) [ Time Frame: at baseline, 6th month ]
    This subscale measures alertness to detail, visual discrimination. The child is asked to identify missing parts of pictures. A primary score ranges from 0 to 20 points. The primary score is further converted into a final score in accordance with the age of the patient. A higher score means better cognitive functioning.

  3. "Block design" subscale of Wechsler Intelligence Scale for Children (WISC) [ Time Frame: at baseline, 6th month ]
    It helps to measure spatial analysis, abstract visual problem-solving. It provides blocks and pictures, and the child must put the blocks together to re-create what's in the picture of the blocks. A primary score ranges from 0 to 55 points. The primary score is further converted into a final score in accordance with the age of the patient. A higher score means better cognitive functioning.

  4. "Coding" subscale of Wechsler Intelligence Scale for Children (WISC) [ Time Frame: at baseline, 6th month ]
    It assesses visual-motor coordination, speed, concentration. Coding A is used for children under age 8. The child is asked to mark rows of shapes with different lines according to a code as quickly as possible for 2 minutes. A primary score ranges (Coding A) from 0 to 50 points. Coding B is used for children aged 8 and older. The child is asked to transcribe a digit-symbol code as quickly as possible for two minutes. A primary score ranges (Coding B) from 0 to 93 points. The primary score is further converted into the final score in accordance with the age of the patient. A higher score means better cognitive functioning.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosed ASD by ICD-10 criteria

Exclusion Criteria:

  • acute somatic diseases
  • indication for surgical (neurosurgical) therapy
  • acute or chronic infectious diseases
  • history of acute allergic reactions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04710810


Locations
Layout table for location information
Russian Federation
St.-Petersburg Bekhterev Reserach Psychoneurological Institute
Saint Petersburg, Санкт-Петербург, Russian Federation, 192019
Sponsors and Collaborators
St. Petersburg Bekhterev Research Psychoneurological Institute
Layout table for additonal information
Responsible Party: St. Petersburg Bekhterev Research Psychoneurological Institute
ClinicalTrials.gov Identifier: NCT04710810    
Other Study ID Numbers: SCA1512
First Posted: January 15, 2021    Key Record Dates
Last Update Posted: January 15, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders